Denka (4061) · InitiativeSoftened
Business partnership with PlexBio on a measurement system
First written in FY2017. 1 of 4 entries say "Advanced", first in FY2019. Latest entry: FY2023.
4entries
7years
0from disclosures
How it moved
Same theme, other companies
Partnership with PlexBio to commercialize a multi-analyte measurement systemA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2023SoftenedAnnual report
「We are working toward an early launch of a sepsis diagnostic product.」
The wording has changed from the previous “launch in fiscal 2022” to “early launch,” without specifying a deadline. - FY2021RestatedAnnual report
「We are working toward the launch of a sepsis diagnostic product in fiscal 2022.」
Reconfirmed the fiscal 2022 launch target for a sepsis diagnostic product using PlexBio's IntelliPlex technology. - FY2019AdvancedAnnual report
「We are also developing a sepsis diagnostic product, targeting launch in fiscal 2022.」
Set a fiscal 2022 launch target for a sepsis diagnostic product using the IntelliPlexTM system through collaboration with PlexBio. - FY2017First statedAnnual report
「デンカ生研株式会社 and PlexBio, our strategic partner headquartered in Taiwan, entered into a business partnership agreement concerning a measurement system developed by PlexBio.」
Entered into a business partnership to promote the adoption of a system capable of rapidly and conveniently measuring multiple proteins and genes.